Cost-effectiveness of a specialized oral nutritional supplementation for malnourished older adult patients in Spain
Resumen: Malnutrition has been related to prolonged hospital stays, and to increases in readmission and mortality rates. In the NOURISH (Nutrition effect On Unplanned Readmissions and Survival in Hospitalized patients) study, administering a high protein oral nutritional supplement (ONS) containing beta-hydroxy-beta-methylbutyrate (HP-HMB) to hospitalised older adult patients led to a significant improvement in survival compared with a placebo treatment. The aim of this study was to determine whether HP-HMB would be cost-effective in Spain. We performed a cost-effectiveness analysis from the perspective of the Spanish National Health System using time horizons of 90 days, 180 days, 1 year, 2 years, 5 years and lifetime. The difference in cost between patients treated with HP-HMB and placebo was €332.75. With the 90 days time horizon, the difference in life years gained (LYG) between both groups was 0.0096, resulting in an incremental cost-effectiveness ratio (ICER) of €34, 700.62/LYG.With time horizons of 180 days, 1 year, 2 years, 5 years and lifetime, the respective ICERs were €13, 711.68, €3377.96, €2253.32, €1127.34 and €563.84/LYG. This analysis suggests that administering HP-HMB to older adult patients admitted to Spanish hospitals during hospitalisation and after discharge could be a cost-effective intervention that would improve survival with a reduced marginal cost.
Idioma: Inglés
DOI: 10.3390/nu10020246
Año: 2018
Publicado en: Nutrients 10, 2 (2018), 246 [11 pp]
ISSN: 2072-6643

Originalmente disponible en: Texto completo de la revista

Factor impacto JCR: 4.171 (2018)
Categ. JCR: NUTRITION & DIETETICS rank: 16 / 86 = 0.186 (2018) - Q1 - T1
Factor impacto SCIMAGO: 1.493 - Nutrition and Dietetics (Q1) - Food Science (Q1)

Tipo y forma: Article (Published version)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.


Exportado de SIDERAL (2020-01-17-21:31:30)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Articles



 Record created 2018-05-08, last modified 2020-01-17


Versión publicada:
 PDF
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)